Badri N. Dasu - Feb 10, 2023 Form 4 Insider Report for ACELRX PHARMACEUTICALS INC (ACRX)

Role: Chief Engineering Officer
Signature: /s/ Martha Adler, Attorney-In-Fact
Stock symbol: ACRX
Transactions as of: Feb 10, 2023
Transactions value $: -$1,304
Form type: 4
Date filed: 2/14/2023, 03:24 PM
Previous filing: Feb 8, 2023
Next filing: Mar 6, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRX	Common Stock	Award	$0	+4.88K	+32.35%	$0.00	19.9K	Feb 10, 2023	Direct	F1, F2
transaction	ACRX	Common Stock	Tax liability	-$1.3K	-776	-3.89%	$1.68	19.2K	Feb 11, 2023	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRX	Stock Option (Right to Buy)	Award	$0	+29.3K		$0.00	29.3K	Feb 10, 2023	Common Stock	29.3K	$1.76	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units shall vest in three equal consecutive annual installments on February 10, 2024, February 10, 2025 and February 10, 2026.
F2	Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F3	Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
F4	On February 10, 2023, the reporting person was granted an option to purchase 29,250 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods.